Sherene Loi

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi request reprint Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
  2. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
  3. doi request reprint Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    S Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Ann Oncol 25:1544-50. 2014
  4. pmc Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 105:960-7. 2013
  5. ncbi request reprint The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
  6. ncbi request reprint Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
  7. doi request reprint Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis
    Michail Ignatiadis
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1996-2004. 2012
  8. doi request reprint Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    Sherene Loi
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 31:860-7. 2013
  9. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
  10. pmc Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment
    Christine Desmedt
    Breast Cancer Translational Research Laboratory JC Heuson, Institut Jules Bordet, 125 Bld de Waterloo, Brussels 1000, Belgium
    Clin Cancer Res 18:1004-14. 2012

Detail Information

Publications51

  1. ncbi request reprint Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  2. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  3. doi request reprint Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    S Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Ann Oncol 25:1544-50. 2014
    ..In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+)...
  4. pmc Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 105:960-7. 2013
    ..This study investigated the frequencies, prognostic effects, and predictive effects of known cancer somatic mutations using a randomized, adjuvant, phase III clinical trial dataset...
  5. ncbi request reprint The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
    ....
  6. ncbi request reprint Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  7. doi request reprint Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis
    Michail Ignatiadis
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1996-2004. 2012
    ..To investigate the association between chemotherapy response and gene expression modules describing important biologic processes and druggable oncogenic pathways in breast cancer (BC) subtypes...
  8. doi request reprint Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    Sherene Loi
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 31:860-7. 2013
    ..We hypothesized that increased lymphocytic infiltration would be associated with good prognosis and benefit from immunogenic CT-in this case, anthracycline-only CT-in selected BC subtypes...
  9. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
    ..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
  10. pmc Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment
    Christine Desmedt
    Breast Cancer Translational Research Laboratory JC Heuson, Institut Jules Bordet, 125 Bld de Waterloo, Brussels 1000, Belgium
    Clin Cancer Res 18:1004-14. 2012
    ..Based on earlier research suggesting that during breast cancer progression, striking changes occur in CD10(+) stromal cells, we aimed to better characterize this cell population and its clinical relevance...
  11. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients...
  12. doi request reprint Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 18:1341-51. 2012
    ..Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age...
  13. doi request reprint Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
    ....
  14. ncbi request reprint Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  15. pmc PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium
    PLoS ONE 8:e53292. 2013
    ..Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better selection of responsive patient populations for mTOR inhibition in combination with letrozole...
  16. doi request reprint Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
    ..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies...
  17. doi request reprint A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
    Lancet Oncol 13:e240-8. 2012
    ..We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer...
  18. pmc Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
    Amir Sonnenblick
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Oncotarget 6:30306-16. 2015
    ..01).In conclusion, in HER2-positive BC, some proteins are associated with distinct gene expression profiles. Our findings identify the ANXA1metagene as a novel biomarker for trastuzumab resistance...
  19. doi request reprint Gene profiling assay and application: the predictive role in primary therapy
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium
    J Natl Cancer Inst Monogr 2011:124-7. 2011
    ....
  20. doi request reprint Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
    Sherene Loi
    Breast International Group, and Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Brussels, Belgium
    Lancet Oncol 12:1162-8. 2011
    ..If possible, patients should be referred at the outset to specialised centres to give them the opportunity to participate in neoadjuvant clinical trials, thereby avoiding several biopsy procedures...
  21. pmc CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
    Sherene Loi
    Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
    Proc Natl Acad Sci U S A 110:11091-6. 2013
    ..Taken together, our data suggest that CD73 constitutes a therapeutic target in TNBC. ..
  22. doi request reprint Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Eur J Cancer 44:2813-8. 2008
    ....
  23. doi request reprint Clinical application of the 70-gene profile: the MINDACT trial
    Fatima Cardoso
    Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 26:729-35. 2008
    ..This article reviews the several steps in the development of the profile from its discovery to its clinical validation...
  24. ncbi request reprint Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
    Jan Bogaerts
    Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Nat Clin Pract Oncol 3:540-51. 2006
    ..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment...
  25. doi request reprint Clinical relevance of host immunity in breast cancer: from TILs to the clinic
    Peter Savas
    Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, East Melbourne, Victoria 8006, Australia
    Nat Rev Clin Oncol 13:228-41. 2016
    ..We also discuss the rationale for enhancing immunity in breast cancer, including early data on the efficacy of T-cell checkpoint inhibition in this setting. ..
  26. doi request reprint Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
    Roberto Salgado
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium2Department of Pathology, Gasthuis Zusters Antwerpen Hospitals, Antwerp, Belgium
    JAMA Oncol 1:448-54. 2015
    ..The prognostic associations in the neoadjuvant setting of other anti-HER2 agents and combinations are unknown...
  27. doi request reprint RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, boulevard de Waterloo, 121, Brussels, BE 1000, Belgium
    Breast Cancer Res 17:538. 2015
    ..No clinical data is available on the effect of pregnancy on RANK/RANKL expression in young breast cancer patients...
  28. doi request reprint Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 39:935-46. 2013
    ..In this article, we present a review of the current relevant pre-clinical and clinical data and discuss the rationale for dual inhibition of these pathways in the treatment of BC patients...
  29. ncbi request reprint Breast cancer gene expression profiling: clinical trial and practice implications
    Sherene Loi
    Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Pharmacogenomics 6:49-58. 2005
    ..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care...
  30. pmc RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
    Sherene Loi
    Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
    Clin Cancer Res 22:1499-509. 2016
    ....
  31. pmc Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
    Amir Sonnenblick
    Breast Cancer Translational Research Laboratory J C Heuson, Institut Jules Bordet, Bld de Waterloo, Universite Libre de Bruxelles, 1000, Brussels, Belgium
    BMC Med 13:177. 2015
    ..We hypothesized that pSTAT3 expression in HER2-positive breast cancer will confer trastuzumab resistance...
  32. doi request reprint Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Dimitrios Zardavas
    BrEAST Data Center, Institut Jules Bordet, Brussels, Belgium
    Curr Opin Oncol 24:623-34. 2012
    ..We review these findings in the context of the preclinical data and the current status of biomarker development in this field...
  33. doi request reprint Biology of breast cancer during pregnancy using genomic profiling
    Hatem A Azim
    Department of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumDepartment of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Department of Forest Ecology
    Endocr Relat Cancer 21:545-54. 2014
    ..No genes were associated with DFS in a multivariate model, which could be due to low statistical power. Diagnosis during pregnancy impacts the breast cancer transcriptome including potential cancer targets...
  34. doi request reprint HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 23:547-58. 2011
    ..We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype...
  35. doi request reprint Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
    Paul A Beavis
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
    Cancer Immunol Res 3:506-17. 2015
    ..Because our studies used SYN-115, a drug that has already undergone phase IIb testing in Parkinson disease, our findings have immediate translational relevance for patients with cancer...
  36. doi request reprint Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy
    Hatem A Azim
    BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Breast 24:290-3. 2015
    ..Tumour infiltrating lymphocytes (TILs) is one of the most exciting breast cancer biomarkers, yet no data is available on its prevalence in tumours diagnosed during pregnancy...
  37. pmc CD4⁺ follicular helper T cell infiltration predicts breast cancer survival
    Chunyan Gu-Trantien
    Molecular Immunology Unit, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Invest 123:2873-92. 2013
    ..Our identification of CD4⁺ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor...
  38. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
    ..CONCLUSION: These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype...
  39. doi request reprint Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy
    Ivana Bozovic-Spasojevic
    BrEAST Data Center, Medical Oncology Department, Institut Jules Bordet, Boulevard de Waterloo 121, Brussels, Belgium Medical Oncology Department, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia Electronic address
    Breast 23:473-81. 2014
    ..BCL2 expression in the TU but not in the LN was predictive of increased benefit to CMF vs anthracycline-based chemotherapy...
  40. doi request reprint Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
    Bradley N Bidwell
    Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia
    Nat Med 18:1224-31. 2012
    ..Thus, we have identified an innate immune pathway intrinsic to breast cancer cells, the suppression of which restricts immunosurveillance to enable metastasis. ..
  41. pmc Relevance of tumor-infiltrating lymphocytes in breast cancer
    Sathana Dushyanthen
    Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    BMC Med 13:202. 2015
    ..Further work is required to determine the immune subsets important in this response and to discover ways of encouraging immune infiltrate in tumor-infiltrating lymphocytes-negative patients. ..
  42. pmc Uncovering the genomic heterogeneity of multifocal breast cancer
    Christine Desmedt
    Breast Cancer Translational Research Laboratory, Universite Libre de Bruxelles, Institut Jules Bordet, Boulevard de Waterloo 121, Brussels, Belgium
    J Pathol 236:457-66. 2015
    ..This implies that deeper molecular characterization of all MFBC lesions is warranted for the adequate management of those cancers...
  43. doi request reprint Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors
    Stephen R Mattarollo
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 71:4809-20. 2011
    ..Overall, these data strongly support the pivotal contribution of both innate and adaptive immunity in treatment outcomes of anthracycline chemotherapy...
  44. doi request reprint Molecular segmentation of luminal breast: Reality in 2015?
    Zhi Ling Teo
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Breast 24:S41-3. 2015
    ..Studies are ongoing to determine which genetic alterations will signify "oncogenic addiction" and which ones will determine resistance and relapse to current standard therapies...
  45. doi request reprint PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer
    Ian J Majewski
    Ian J Majewski, Lorenza Mittempergher, Astrid J Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz Delgado, Vall D Hebron Institute of Oncology Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain Holger Eidtmann, University Hospital Kiel, Kiel Nadia Harbeck, University of Munich, Munich, Germany Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom Christos Sotiriou, Debora Fumagalli, and Martine Piccart Gebhart, Institut Jules Bordet, Université Libre de Bruxelles Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Catherine Ellis, GlaxoSmithKline, Collegeville, PA and Nikolaus Schultz and José Baselga
    J Clin Oncol 33:1334-9. 2015
    ....
  46. ncbi request reprint Obesity and outcomes in premenopausal and postmenopausal breast cancer
    Sherene Loi
    Peter MacCallum Cancer Centre, 723 Swanston Street, Carlton, Victoria 3053, Australia
    Cancer Epidemiol Biomarkers Prev 14:1686-91. 2005
    ..Obesity is associated with adverse outcomes in postmenopausal women with breast cancer. In premenopausal women, the association is less clear...
  47. pmc Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
    John Stagg
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
    Proc Natl Acad Sci U S A 108:7142-7. 2011
    ..We demonstrate that anti-PD-1 or anti-CD137 mAb can significantly improve the therapeutic activity of anti-ErbB-2 mAb in immunocompetent mice...
  48. pmc Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
    Carmen Criscitiello
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels
    Onco Targets Ther 4:1-11. 2011
    ..A combination of gene expression and genetic aberration markers may be most useful in discerning a population that is still appropriate for adjuvant tamoxifen treatment...
  49. ncbi request reprint Challenges in breast cancer clinical trial design in the postgenomic era
    Sherene Loi
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Curr Opin Oncol 16:536-41. 2004
    ..The neoadjuvant setting presents a unique opportunity to test new concepts in a previously untreated patient population, because they may yield preliminary answers in a shorter time than that required in adjuvant trials...
  50. ncbi request reprint Molecular forecasting of breast cancer: time to move forward with clinical testing
    Sherene Loi
    J Clin Oncol 24:721-2; author reply 722-3. 2006